Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects

Simple Summary: Nilotinib and other tyrosine kinase inhibitors (TKIs) target the BCR-ABL1 oncoprotein in Chronic Myeloid Leukemia (CML), reducing the growth of leukemic stem cells (LSCs) and promoting their death. However, some LSCs persist in the bone marrow (BM), which may lead to relapse and dise...

Full description

Bibliographic Details

Published in:	Cancers Vol. 17; no. 6; pp. 1022 - 1036
Main Authors:	Trojani, Alessandra, Pungolino, Ester, Di Camillo, Barbara, Bossi, Luca Emanuele, Palumbo, Cassandra, D'adda, Mariella, Perego, Alessandra, Turrini, Mauro, Elena, Chiara, Borin, Lorenza Maria, Iurlo, Alessandra, Malato, Simona, Spina, Francesco, Latargia, Maria Luisa, Spedini, Pierangelo, Artale, Salvatore, Anghilieri, Michela, Carraro, Maria Cristina, Bucelli, Cristina, Beghini, Alessandro
Format:	research tables/charts Journal Article
Published:	MDPI Mar2025
Online Access:	View this record in EBSCOhost